ReviewJournal of clinical medicine2024
Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.Cancer medicine · 2025Pooled it
- Liver Disease and Plant-Derived Phytoconstituents: From Ethnopharmacology to Modern Medicine.Phytotherapy research : PTR · 2026Review
- The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.Hepatology international · 2026Article
- Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B.Scientific reports · 2026Article
- Comparative analysis of the predictive value of the ASAP model and the GAAD model for liver cancer high risk cohorts.Scientific reports · 2026Article
- Current advances and future directions in the management of HBV-related hepatocellular carcinoma.Gastroenterology report · 2026Review
- Article
- Personalized Mortality Risk Stratification in ALD- and MASLD-Related Hepatocellular Carcinoma Using a Machine Learning Approach.Metabolites · 2025Article
- Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.Hepatology (Baltimore, Md.) · 2025Article
- A comprehensive review of mycotoxins, their toxicity, and innovative detoxification methods.Toxicology reports · 2025Review
- Comparative performance of the GAAD and ASAP scores in predicting early-stage hepatocellular carcinoma.Gastroenterology report · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, primarily developing in the context of chronic liver disease. Traditional prevention has focused on liver-specific interventions like antiviral therapies and surveillance. However, extrahepatic factors also significantly contribute to HCC risk. This review explores comprehensive strategies for HCC prevention, including both hepatic and extrahepatic factors.
methodsAn extensive literature search of peer-reviewed articles up to October 2024 was conducted, focusing on studies addressing HCC prevention strategies. Studies that focused on both hepatic and extrahepatic factors were included. Data were extracted and synthesized to provide an overview of current prevention strategies and their effectiveness in reducing HCC incidence.
resultsHepatitis B vaccination and antiviral treatments for hepatitis B and C significantly reduce HCC incidence. Lifestyle modifications-such as reducing alcohol consumption, maintaining a healthy weight through diet and exercise, and smoking cessation-are crucial in lowering HCC risk. Environmental measures to limit exposure to aflatoxins and other hazards also contribute to prevention. Regular surveillance of high-risk groups enables early detection and improves survival rates. Emerging strategies like immunotherapy and gene therapy show potential for further reducing HCC risk.
conclusionsA comprehensive approach combining medical interventions, lifestyle changes, and environmental controls is essential for effectively decreasing HCC incidence globally. Implementing these combined measures could significantly reduce the global burden of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.